ECONOMIC BURDEN OF MODERATE AND SEVERE HEMOPHILIA A AND B IN SPAIN, REAL-WORLD EVIDENCE INSIGHTS FROM THE COST OF HEMOPHILIA IN EUROPE: A SOCIO-ECONOMIC SURVEY II (CHESS II) STUDY

被引：0
|
作者：
Peral, C. [1 ]
De Lossada Juste, A. [1 ]
Lwoff, N. [1 ]
Espinoza Camac, N. [2 ]
Martinez, N. [3 ]
Casado, M. A. [2 ]
Burke, T. [4 ]
Kane, A. [5 ]
Alvir, J. [5 ]
Thakkar, S. [5 ]
Grazzi, Ferri E. [4 ,6 ]
机构：
[1] Pfizer SLU, Madrid, Spain
[2] Pharmacoecon & Outcomes Res Iberia PORIB, Madrid, Spain
[3] PORIB Employee, Madrid, Spain
[4] HCD Econ, Warrington, Cheshire, England
[5] Pfizer Inc, New York, NY USA
[6] HCD Econ, Daresbury, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD22
引用
收藏
页码：S508 / S508
页数：1
相关论文
共 29 条
  • [21] REAL-WORLD CLINICAL OUTCOMES IN PEOPLE FROM ACROSS EUROPE WITH SEVERE HAEMOPHILIA B RECEIVING FIX PROPHYLAXIS: AN ANALYSIS OF CHESS II
    Burke, T.
    Asghar, S.
    O'Hara, J.
    Chuang, M.
    Sawyer, E.
    Li, N. N.
    HAEMOPHILIA, 2021, 27 : 115 - 115
  • [22] BURDEN OF ILLNESS OF HAEMOPHILIA A PATIENTS USING DATA FROM CHESS II, A EUROPEAN REAL-WORLD DATA STUDY
    Young, L.
    Loftus, J.
    Chen, Y.
    Alvir, J.
    Chi, L.
    King, A.
    Winburn, I.
    HAEMOPHILIA, 2020, 26 : 95 - 95
  • [23] INDIRECT BURDEN ASSOCIATED WITH PRODUCTIVITY LOSS IN HAEMOPHILIA A & B - USING DATA FROM CHESS II - A EUROPEAN REAL-WORLD DATA STUDY
    Young, L.
    Markson, L.
    Chen, Y.
    Chi, L.
    Alvir, J.
    Burke, T.
    Asghar, S.
    Winburn, I.
    HAEMOPHILIA, 2021, 27 : 91 - 91
  • [24] Vildagliptin is cost-effective in real-world: economic evaluation evidence from EDGE study
    Partha, G.
    Agrawal, R.
    Paldanius, P. M.
    Viana, R.
    DIABETOLOGIA, 2015, 58 : S481 - S481
  • [25] Socio-economic inequality in the nutritional deficiencies among the world countries: evidence from global burden of disease study 2019
    Bayati, Mohsen
    Arkia, Elham
    Emadi, Mehrnoosh
    JOURNAL OF HEALTH POPULATION AND NUTRITION, 2025, 44 (01)
  • [26] Health-related quality of life and chronic pain burden on a cohort of people with haemophilia in 5 European countries: An updated snapshot from the cost of haemophilia in Europe: A longitudinal socio-economic survey (chess)
    O'Mahony, Brian
    Mancuso, Maria Elisa
    Brighton, Sarah
    Smith, Clive
    Garcia Diego, Daniel-Anibal
    Arzenton, Matteo
    Sannie, Thomas
    Curtis, Randall
    Coffin, Donna
    Brennan, Fiona
    Evans, Jonathan
    Burke, Tom
    Grazzi, Enrico Ferri
    HAEMOPHILIA, 2024, 30 : 169 - 170
  • [27] THE ECONOMIC BURDEN OF SEVERE HAEMOPHILIA A WITHOUT INHIBITORS AMONG ADULTS WITH HEALTH INSURANCE COVERAGE IN THE UNITED STATES: INSIGHTS FROM THE "COST OF HAEMOPHILIA ACROSS THE US: A SOCIOECONOMIC SURVEY" CHESS US AND CHESS US plus STUDIES
    Grazzi, Ferri E.
    Blenkiron, T.
    O'Hara, J.
    Chen, E.
    Hinds, D.
    Burke, T.
    VALUE IN HEALTH, 2022, 25 (07) : S339 - S339
  • [28] REAL-WORLD UTILIZATION, TREATMENT FREQUENCY, AND BLEEDING OUTCOMES ON DAMOCTOCOG ALFA PEGOL IN HAEMOPHILIA A CARE: INSIGHTS FROM A GERMAN COHORT WITHIN THE CHESS II STUDY
    Zhang, W.
    Grazzi, E. Ferri
    O'Hara, J.
    Burke, T.
    VALUE IN HEALTH, 2022, 25 (12) : S125 - S125
  • [29] Endogenous fix expression and reduced annual bleed rate following AMT-060 (AAV-HFIX) in adults with severe or moderate-severe hemophilia B: Interim results up to 1.5 years from a phase I/II dose-escalation study
    Miesbach, W.
    Meijer, K.
    Coppens, M.
    Kampmann, P.
    Klamroth, R.
    Schutgens, R.
    Castaman, G.
    Seifreid, E.
    Schwable, J.
    Boeig, H.
    Sawyer, E.
    Leebeek, F.
    HAEMOPHILIA, 2018, 24 : 31 - 31
123